Biotech stocks offer high-risk, high-reward opportunities in the race for breakthrough therapies. Ligand Pharmaceuticals (LGND) stands out, with a market cap of $3.9 billion and a diverse drug portfolio generating significant revenue. Ligand anticipates a 40% growth in royalty revenue for 2026, backed by strategic acquisitions and a robust commercial portfolio.

Kinnate Biopharma (KNSA) focuses on precision oncology therapies, with flagship drug ARCALYST driving strong revenue growth. Third-quarter revenue hit $180.9 million, marking substantial growth year-over-year. ARCALYST targets specific proteins to treat recurrent pericarditis and shows potential for further expansion, offering growth opportunities for investors.

Ascendis Pharma (ASND) specializes in rare-disease treatments, delivering groundbreaking results in achondroplasia treatment. The COACH trial demonstrated unprecedented growth rates, exceeding previous standards. The company plans to move forward with a Phase 3 trial, positioning itself as a leader in transforming treatment for this challenging condition. Analysts recommend buying ASND stock, with a price target of $259.

Read more at Yahoo Finance: Gamble on Huge Gains with These 3 Best Biotech Stocks to Buy for 2026